1knu › Citations

Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Wöldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM
J Med Chem 45 789-804 (2002)
Cited: 70 times
EuropePMC logo PMID: 11831892

Abstract

Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro. Ten days treatment of db/db mice with 3q improved the insulin sensitivity, as measured by OGTT, better than that seen with both pioglitazone and rosiglitazone treatment, suggesting in vivo PPARgamma activity. Likewise, 3q lowered plasma triglycerides and cholesterol in high cholesterol fed rats after 4 days treatment, indicating in vivo PPARalpha activity. Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds.

Articles - 1knu mentioned but not cited (7)

  1. Predicting new indications for approved drugs using a proteochemometric method. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW. J Med Chem 55 6832-6848 (2012)
  2. Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles. Park SJ, Kufareva I, Abagyan R. J Comput Aided Mol Des 24 459-471 (2010)
  3. Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. Guasch L, Sala E, Castell-Auví A, Cedó L, Liedl KR, Wolber G, Muehlbacher M, Mulero M, Pinent M, Ardévol A, Valls C, Pujadas G, Garcia-Vallvé S. PLoS One 7 e50816 (2012)
  4. Virtual Screening as a Technique for PPAR Modulator Discovery. Lewis SN, Bassaganya-Riera J, Bevan DR. PPAR Res 2010 861238 (2010)
  5. Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis. Tsakovska I, Al Sharif M, Alov P, Diukendjieva A, Fioravanzo E, Cronin MT, Pajeva I. Int J Mol Sci 15 7651-7666 (2014)
  6. Anti-Alzheimer's Disease Molecular Mechanism of Acori Tatarinowii Rhizoma Based on Network Pharmacology. Zhang Y, Wu Y, Fu Y, Lin L, Lin Y, Zhang Y, Ji L, Li C. Med Sci Monit Basic Res 26 e924203 (2020)
  7. Fucoxanthin ameliorates oxidative injury and inflammation of human bronchial epithelial cells induced by cigarette smoke extract via the PPARγ/NF‑κB signaling pathway. Chen S, Zhu L, Li J. Exp Ther Med 25 69 (2023)


Reviews citing this publication (14)

  1. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Marx N, Duez H, Fruchart JC, Staels B. Circ Res 94 1168-1178 (2004)
  2. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Li AC, Glass CK. J Lipid Res 45 2161-2173 (2004)
  3. High-density lipoprotein and coronary heart disease: current and future therapies. Natarajan P, Ray KK, Cannon CP. J Am Coll Cardiol 55 1283-1299 (2010)
  4. Evolution of peroxisome proliferator-activated receptor agonists. Chang F, Jaber LA, Berlie HD, O'Connell MB. Ann Pharmacother 41 973-983 (2007)
  5. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease. Lebovitz HE. Diabetes Obes Metab 8 237-249 (2006)
  6. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Li AC, Palinski W. Annu Rev Pharmacol Toxicol 46 1-39 (2006)
  7. Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Parrill AL, Sardar VM, Yuan H. Semin Cell Dev Biol 15 467-476 (2004)
  8. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. van Oostrom AJ, van Wijk J, Cabezas MC. Drugs 64 Suppl 2 19-41 (2004)
  9. PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014). Takada I, Makishima M. Expert Opin Ther Pat 25 175-191 (2015)
  10. Selective PPAR agonists for the treatment of type 2 diabetes. Nehlin JO, Mogensen JP, Petterson I, Jeppesen L, Fleckner J, Wulff EM, Sauerberg P. Ann N Y Acad Sci 1067 448-453 (2006)
  11. Triglyceride-lowering agents. Salakhutdinov NF, Laev SS. Bioorg Med Chem 22 3551-3564 (2014)
  12. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Beckman J, Raji A, Plutzky J. Curr Opin Cardiol 18 479-485 (2003)
  13. Therapeutic applications of the versatile fatty acid mimetic WY14643. Pollinger J, Merk D. Expert Opin Ther Pat 27 517-525 (2017)
  14. Treatment of non-insulin-dependent diabetes mellitus. Patel M, Rybczynski PJ. Expert Opin Investig Drugs 12 623-633 (2003)

Articles citing this publication (49)

  1. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR. Structure 15 1258-1271 (2007)
  2. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Ye JM, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, Sørensen RV, Larsen PJ, Cooney GJ, Wassermann K, Kraegen EW. Am J Physiol Endocrinol Metab 284 E531-40 (2003)
  3. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. Ljung B, Bamberg K, Dahllöf B, Kjellstedt A, Oakes ND, Ostling J, Svensson L, Camejo G. J Lipid Res 43 1855-1863 (2002)
  4. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR, Ragaglitazar Dose-Ranging Study Group. Diabetes Care 27 1324-1329 (2004)
  5. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C. Arterioscler Thromb Vasc Biol 25 1897-1902 (2005)
  6. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Pickavance LC, Brand CL, Wassermann K, Wilding JP. Br J Pharmacol 144 308-316 (2005)
  7. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K. Am J Physiol Endocrinol Metab 284 E841-54 (2003)
  8. Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles. Frederiksen KS, Wulff EM, Sauerberg P, Mogensen JP, Jeppesen L, Fleckner J. J Lipid Res 45 592-601 (2004)
  9. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. Ambrosio ALB, Dias SMG, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. J Biol Chem 282 18625-18633 (2007)
  10. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B. J Clin Pharmacol 43 1244-1256 (2003)
  11. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Märki HP, Meyer M, Mohr P. Bioorg Med Chem Lett 16 4016-4020 (2006)
  12. Pharmacophore modeling and parallel screening for PPAR ligands. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T. J Comput Aided Mol Des 21 575-590 (2007)
  13. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rücker C. Mol Pharmacol 71 398-406 (2007)
  14. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Eur J Pharmacol 596 173-179 (2008)
  15. Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action. Miglio G, Rosa AC, Rattazzi L, Grange C, Camussi G, Fantozzi R. Br J Pharmacol 167 641-653 (2012)
  16. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Verreth W, Ganame J, Mertens A, Bernar H, Herregods MC, Holvoet P. Arterioscler Thromb Vasc Biol 26 922-928 (2006)
  17. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. da Costa Leite LF, Veras Mourão RH, de Lima Mdo C, Galdino SL, Hernandes MZ, de Assis Rocha Neves F, Vidal S, Barbe J, da Rocha Pitta I. Eur J Med Chem 42 1263-1271 (2007)
  18. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Martín JA, Brooks DA, Prieto L, González R, Torrado A, Rojo I, López de Uralde B, Lamas C, Ferritto R, Dolores Martín-Ortega M, Agejas J, Parra F, Rizzo JR, Rhodes GA, Robey RL, Alt CA, Wendel SR, Zhang TY, Reifel-Miller A, Montrose-Rafizadeh C, Brozinick JT, Hawkins E, Misener EA, Briere DA, Ardecky R, Fraser JD, Warshawsky AM. Bioorg Med Chem Lett 15 51-55 (2005)
  19. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. Eur J Pharmacol 595 119-125 (2008)
  20. 3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA. Liao C, Xie A, Zhou J, Shi L, Li Z, Lu XP. J Mol Model 10 165-177 (2004)
  21. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity. Fracchiolla G, Laghezza A, Piemontese L, Carbonara G, Lavecchia A, Tortorella P, Crestani M, Novellino E, Loiodice F. ChemMedChem 2 641-654 (2007)
  22. Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants. Kumar R, Ramachandran U, Srinivasan K, Ramarao P, Raichur S, Chakrabarti R. Bioorg Med Chem 13 4279-4290 (2005)
  23. Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein. Fidelak J, Ferrer S, Oberlin M, Moras D, Dejaegere A, Stote RH. Eur Biophys J 39 1503-1512 (2010)
  24. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC. Bioorg Med Chem Lett 18 1617-1622 (2008)
  25. Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists. Tanrikulu Y, Rau O, Schwarz O, Proschak E, Siems K, Müller-Kuhrt L, Schubert-Zsilavecz M, Schneider G. Chembiochem 10 75-78 (2009)
  26. A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Sakamoto J, Kimura H, Moriyama S, Imoto H, Momose Y, Odaka H, Sawada H. Eur J Pharmacol 495 17-26 (2004)
  27. Synthesis and biological evaluation of new clofibrate analogues as potential PPARalpha agonists. Perrone MG, Santandrea E, Dell'Uomo N, Giannessi F, Milazzo FM, Sciarroni AF, Scilimati A, Tortorella V. Eur J Med Chem 40 143-154 (2005)
  28. Catalytic asymmetric epoxidation of alpha,beta-unsaturated esters with chiral yttrium-biaryldiol complexes. Kakei H, Tsuji R, Ohshima T, Morimoto H, Matsunaga S, Shibasaki M. Chem Asian J 2 257-264 (2007)
  29. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC. Drug Des Devel Ther 7 279-288 (2013)
  30. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC. Bioorg Med Chem Lett 19 2683-2687 (2009)
  31. Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Mogensen JP, Jeppesen L, Bury PS, Pettersson I, Fleckner J, Nehlin J, Frederiksen KS, Albrektsen T, Din N, Mortensen SB, Svensson LA, Wassermann K, Wulff EM, Ynddal L, Sauerberg P. Bioorg Med Chem Lett 13 257-260 (2003)
  32. Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists. Yu J, Tang L, Yang Y, Ji R. Eur J Med Chem 43 2428-2435 (2008)
  33. Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators. Dixit VA, Rathi PC, Bhagat S, Gohlke H, Petersen RK, Kristiansen K, Chakraborti AK, Bharatam PV. Eur J Med Chem 108 423-435 (2016)
  34. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity. Le Naour M, Leclerc V, Farce A, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Lonchampt M, Dacquet C, Ktorza A, Berthelot P, Lebegue N. ChemMedChem 7 2179-2193 (2012)
  35. Structure-activity relationships of dimeric PPAR agonists. Sauerberg P, Mogensen JP, Jeppesen L, Svensson LA, Fleckner J, Nehlin J, Wulff EM, Pettersson I. Bioorg Med Chem Lett 15 1497-1500 (2005)
  36. Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. Felts AS, Siegel BS, Young SM, Moth CW, Lybrand TP, Dannenberg AJ, Marnett LJ, Subbaramaiah K. J Med Chem 51 4911-4919 (2008)
  37. Facile synthesis of optically pure (S)-3-p-hydroxyphenyllactic acid derivatives. Zeng QL, Wang HQ, Liu ZR, Li BG, Zhao YF. Amino Acids 33 537-541 (2007)
  38. 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity. Dell'Uomo N, Tassoni E, Brunetti T, Pessotto P, Sciarroni AF, Milazzo FM, De Angelis F, Peschechera A, Tinti MO, Carminati P, Giannessi F. ChemMedChem 1 49-53 (2006)
  39. Determination of ragaglitazar, a novel dual acting peroxisome proliferator-activated receptor (PPAR) alpha and -gamma agonist, in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. Andersen MP, Nielsen KK. J Chromatogr B Analyt Technol Biomed Life Sci 788 45-55 (2003)
  40. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. Jiang Z, Liu X, Yuan Z, He H, Wang J, Zhang X, Gong Z, Hou L, Shen L, Guo F, Zhang J, Wang J, Xu D, Liu Z, Li H, Chen X, Long C, Li J, Chen S. ACS Med Chem Lett 10 1068-1073 (2019)
  41. Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents. Chaturvedi D, Ray S, Srivastava AK, Chander R. Bioorg Med Chem 16 2489-2498 (2008)
  42. Prospective QSAR-based prediction models with pharmacophore studies of oxadiazole-substituted α-isopropoxy phenylpropanoic acids on with dual activators of PPARα and PPARγ Sharma MC. Interdiscip Sci (2014)
  43. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists. Shioi R, Okazaki S, Noguchi-Yachide T, Ishikawa M, Makishima M, Hashimoto Y, Yamaguchi T. Bioorg Med Chem Lett 27 3131-3134 (2017)
  44. To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. Sullivan HJ, Wang X, Nogle S, Liao S, Wu C. PPAR Res 2020 5314187 (2020)
  45. TFAA/H3PO4 mediated unprecedented N-acylation of carbazoles leading to small molecules possessing anti-proliferative activities against cancer cells. Kolli SK, Prasad B, Babu PV, Ashfaq MA, Ehtesham NZ, Raju RR, Pal M. Org Biomol Chem 12 6080-6084 (2014)
  46. A tandem regression-outlier analysis of a ligand cellular system for key structural modifications around ligand binding. Lin YT. J Cheminform 5 21 (2013)
  47. Design of potent PPARalpha agonists. Sauerberg P, Mogensen JP, Jeppesen L, Bury PS, Fleckner J, Olsen GS, Jeppesen CB, Wulff EM, Pihera P, Havranek M, Polivka Z, Pettersson I. Bioorg Med Chem Lett 17 3198-3202 (2007)
  48. High speed development work by preparation of an "in-hand" library of NMR-quantified degradation products. Malmstrøm J, Hansen L, Ryager A, Olsen H. J Pharm Sci 94 2549-2567 (2005)
  49. Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted α-Isopropoxy Phenylpropanoic Acids with Dual Activators of PPARα and PPARγ. Sharma MC. Interdiscip Sci 7 335-345 (2015)


Quick links